Title |
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement
|
---|---|
Published in |
Clinical Pharmacokinetics, January 2015
|
DOI | 10.1007/s40262-015-0236-8 |
Pubmed ID | |
Authors |
Salmaan Kanji, Meghan Hayes, Adam Ling, Larissa Shamseer, Clarence Chant, David J. Edwards, Scott Edwards, Mary H. H. Ensom, David R. Foster, Brian Hardy, Tyree H. Kiser, Charles la Porte, Jason A. Roberts, Rob Shulman, Scott Walker, Sheryl Zelenitsky, David Moher |
Abstract |
Transparent reporting of all research is essential for assessing the validity of any study. Reporting guidelines are available and endorsed for many types of research but are lacking for clinical pharmacokinetic studies. Such tools promote the consistent reporting of a minimal set of information for end users, and facilitate knowledge translation of research. The objective of this study was to create a guideline to assist in the transparent and complete reporting of clinical pharmacokinetic studies. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 3 | 38% |
Chile | 1 | 13% |
United States | 1 | 13% |
Canada | 1 | 13% |
Unknown | 2 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 63% |
Scientists | 2 | 25% |
Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Denmark | 1 | 1% |
France | 1 | 1% |
Canada | 1 | 1% |
Unknown | 89 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 15% |
Student > Ph. D. Student | 13 | 14% |
Student > Master | 9 | 10% |
Student > Doctoral Student | 9 | 10% |
Other | 7 | 8% |
Other | 17 | 18% |
Unknown | 23 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 29% |
Pharmacology, Toxicology and Pharmaceutical Science | 21 | 23% |
Nursing and Health Professions | 5 | 5% |
Biochemistry, Genetics and Molecular Biology | 3 | 3% |
Chemistry | 3 | 3% |
Other | 7 | 8% |
Unknown | 26 | 28% |